MX378320B - Nuevos procedimientos de fabricacion de barusiban y sus intermedios. - Google Patents
Nuevos procedimientos de fabricacion de barusiban y sus intermedios.Info
- Publication number
- MX378320B MX378320B MX2018004282A MX2018004282A MX378320B MX 378320 B MX378320 B MX 378320B MX 2018004282 A MX2018004282 A MX 2018004282A MX 2018004282 A MX2018004282 A MX 2018004282A MX 378320 B MX378320 B MX 378320B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- barusiban
- intermediates
- manufacturing procedures
- new manufacturing
- Prior art date
Links
- 108010040145 barusiban Proteins 0.000 title abstract 2
- UGNGRKKDUVKQDF-IHOMMZCZSA-N barusiban Chemical compound N1C(=O)CCSCC[C@@H](C(=O)N(C)[C@H](CO)CCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]1CC1=CNC2=CC=CC=C12 UGNGRKKDUVKQDF-IHOMMZCZSA-N 0.000 title abstract 2
- 229950009748 barusiban Drugs 0.000 title abstract 2
- 239000000543 intermediate Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 abstract 2
- 239000007790 solid phase Substances 0.000 abstract 2
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003336 oxytocin antagonist Substances 0.000 abstract 1
- 229940121361 oxytocin antagonists Drugs 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 235000019260 propionic acid Nutrition 0.000 abstract 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
La presente invención se refiere a nuevos procedimientos de péptidos en fase sólida de síntesis de análogos que presentan actividad antagonista de oxitocina, específicamente barusiban y sus intermedios. Específicamente, la presente invención se refiere a un procedimiento en fase sólida de preparación de un compuesto que tiene la fórmula c[AA1-AA6]-AA7-ol, en la que AA1 es ácido propiónico, AA2 es preferiblemente D-Trp, AA3 es Ile, AA4 es preferiblemente AlloIle, AA5 es Asn, AA6 es hCy, y AA7 es preferiblemente N-Me-Orn-ol, o una sal o solvato farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15188529 | 2015-10-06 | ||
| PCT/EP2016/073858 WO2017060339A1 (en) | 2015-10-06 | 2016-10-06 | New methods for making barusiban and its intermediates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004282A MX2018004282A (es) | 2018-08-09 |
| MX378320B true MX378320B (es) | 2025-03-10 |
Family
ID=54288657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004282A MX378320B (es) | 2015-10-06 | 2016-10-06 | Nuevos procedimientos de fabricacion de barusiban y sus intermedios. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180282367A1 (es) |
| EP (1) | EP3359557A1 (es) |
| JP (1) | JP2018535946A (es) |
| KR (1) | KR20180059549A (es) |
| CN (1) | CN108290929A (es) |
| AU (1) | AU2016335061B2 (es) |
| CA (1) | CA3001057A1 (es) |
| MX (1) | MX378320B (es) |
| RU (1) | RU2726414C2 (es) |
| WO (1) | WO2017060339A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018015497A2 (en) | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CN110894212B (zh) * | 2018-08-24 | 2021-06-04 | 翰宇药业（武汉）有限公司 | 一种合成依替巴肽硫醚的方法 |
| AU2020340670A1 (en) | 2019-09-03 | 2022-04-07 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| WO2021160597A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE501678C2 (sv) * | 1993-07-13 | 1995-04-10 | Ferring Bv | Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid |
| SE9604341D0 (sv) | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
| AU2003211011A1 (en) * | 2002-02-27 | 2003-09-09 | Ferring Bv | Intermediates and methods for making heptapeptide oxytocin analogues |
| TWI463990B (zh) * | 2009-09-21 | 2014-12-11 | Ferring Bv | 催產素受體促進劑 |
| CN102875650B (zh) * | 2012-09-26 | 2014-06-11 | 深圳翰宇药业股份有限公司 | 巴卢西班的制备方法 |
-
2016
- 2016-10-06 EP EP16778343.0A patent/EP3359557A1/en not_active Withdrawn
- 2016-10-06 WO PCT/EP2016/073858 patent/WO2017060339A1/en not_active Ceased
- 2016-10-06 KR KR1020187012844A patent/KR20180059549A/ko not_active Withdrawn
- 2016-10-06 MX MX2018004282A patent/MX378320B/es unknown
- 2016-10-06 CA CA3001057A patent/CA3001057A1/en not_active Abandoned
- 2016-10-06 CN CN201680058334.1A patent/CN108290929A/zh active Pending
- 2016-10-06 AU AU2016335061A patent/AU2016335061B2/en not_active Expired - Fee Related
- 2016-10-06 JP JP2018517557A patent/JP2018535946A/ja active Pending
- 2016-10-06 RU RU2018116568A patent/RU2726414C2/ru active
- 2016-10-06 US US15/765,933 patent/US20180282367A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180059549A (ko) | 2018-06-04 |
| CN108290929A (zh) | 2018-07-17 |
| MX2018004282A (es) | 2018-08-09 |
| US20180282367A1 (en) | 2018-10-04 |
| WO2017060339A1 (en) | 2017-04-13 |
| EP3359557A1 (en) | 2018-08-15 |
| RU2018116568A (ru) | 2019-11-07 |
| CA3001057A1 (en) | 2017-04-13 |
| JP2018535946A (ja) | 2018-12-06 |
| AU2016335061A1 (en) | 2018-04-19 |
| RU2018116568A3 (es) | 2020-01-27 |
| RU2726414C2 (ru) | 2020-07-14 |
| AU2016335061B2 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790407A1 (ru) | Зонды для визуализации белка хантингтина | |
| ZA202000411B (en) | Polymorphs of 5-fluoro-4-imino-3-methyl-1-tosyl-3,4-dihydropyrimidin-2-one | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| CY1119731T1 (el) | Διαδικασια για την παρασκευη παραγωγων χολικου οξεος | |
| JOP20180113A1 (ar) | مركبات ,تركيبات وطرق | |
| WO2015110897A3 (en) | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| SA520411406B1 (ar) | مركبات مثبطة لمستقبل حمض ليسوفوسفاتيديك 1 | |
| EA201790983A1 (ru) | Синтез копанлисиба и его дигидрохлорида | |
| EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
| EA201790400A1 (ru) | Зонды для визуализации белка хантингтина | |
| EP3404032A3 (en) | Process for making benzoxazepin compounds | |
| EA201992421A1 (ru) | Способ получения озанимода | |
| MY183123A (en) | Synthesis of copanlisib and its di hydrochloride salt | |
| MX378320B (es) | Nuevos procedimientos de fabricacion de barusiban y sus intermedios. | |
| WO2015068175A3 (en) | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| MX2019001228A (es) | Metodo de produccion del compuesto de pirazol-amida. | |
| EA201891431A1 (ru) | Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина | |
| BR112017003715A2 (pt) | método para sintetizar peneiras moleculares de silicoaluminofosfato-34 usando monoisopropanol amina | |
| AR100095A1 (es) | Formas sólidas del ácido {[(2r,3s,4r,5s)-4-(4-cloro-2-fluoro-fenil)-3-(3-cloro-2-fluoro-fenil)-4-ciano-5-(2,2-dimetil-propil)-pirrolidin-2-carbonil]-amino}-3-metoxi-benzoico | |
| EA201690908A1 (ru) | Пиразолопиримидиновые соединения | |
| WO2016202808A3 (en) | NEW SYNTHESIS OF TAPENTADOL-HCl INTERMEDIATES | |
| WO2015104602A3 (en) | A process for the preparation of anagliptin and its intermediates thereof | |
| UY35561A (es) | Procedimiento de síntesis del 3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trien-7- carbonitrilo, y aplicación a la síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable |